CTLA4 and myeloid sarcoma: Harbo et al. have shown that the CTLA-4 exon 1 (+49)- heterozygous A-G genotype is significantly higher in Norwegian MS patients in comparison to healthy controls, whereas the CTLA-4 promoter (a318) dimorphism is not involved in genetic susceptibility [115].